InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,959.76
(
0.26%
)
Post# of 251798
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119615
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: marthambles post# 215857

Saturday, 12/09/2017 12:41:09 PM

Saturday, December 09, 2017 12:41:09 PM

Post# of 251798
Re: Re: RVNC trial in plantar fasciitis

What I am proposing is the possibility of data coming from the trial which would be suggestive of superiority to Botox. Obviously it could only be suggestive because comparisons would have to be made across trials. Failing this, RVNC would simply be an equal competitor in a small PF market where AGN's marketing clout would dominate.

If RVNC eventually gets FDA approval for treating plantar fasciitis (something that no other botulinum toxin has), it will facilitate reimbursement for treating PF and will likely give RT002 a dominant market share in this indication.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up